A citation-based method for searching scientific literature

Edna T Kimura, Marina N Nikiforova, Zhaowen Zhu, Jeffrey A Knauf, Yuri E Nikiforov, James A Fagin. Cancer Res 2003
Times Cited: 1151







List of co-cited articles
721 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
24


BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Paula Soares, Vítor Trovisco, Ana Sofia Rocha, Jorge Lima, Patrícia Castro, Ana Preto, Valdemar Máximo, Tiago Botelho, Raquel Seruca, Manuel Sobrinho-Simões. Oncogene 2003
489
19

BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
897
18

BRAF mutation in papillary thyroid carcinoma.
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo, Zhongmin Guo, Guogun Wu, Barry Trink, Uziel Beller, William H Westra, Paul W Ladenson, David Sidransky. J Natl Cancer Inst 2003
618
18

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
18

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
464
17

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
568
16

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Marina N Nikiforova, Edna T Kimura, Manoj Gandhi, Paul W Biddinger, Jeffrey A Knauf, Fulvio Basolo, Zhaowen Zhu, Riccardo Giannini, Giuliana Salvatore, Alfredo Fusco,[...]. J Clin Endocrinol Metab 2003
746
15

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
690
13


BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
382
12

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
543
12

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
732
11

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
413
11

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
363
11

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
10

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
178
10

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
296
10

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
352
10

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Yasuhiro Ito, Hiroshi Yoshida, Rie Maruo, Shinji Morita, Toru Takano, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda,[...]. Endocr J 2009
185
10

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
Norisato Mitsutake, Jeffrey A Knauf, Shin Mitsutake, Cleo Mesa, Lei Zhang, James A Fagin. Cancer Res 2005
159
9

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
258
9

Current thyroid cancer trends in the United States.
Louise Davies, H Gilbert Welch. JAMA Otolaryngol Head Neck Surg 2014
883
8

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo. J Clin Endocrinol Metab 2008
359
8

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
732
8

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
151
8

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
Adebowale J Adeniran, Zhaowen Zhu, Manoj Gandhi, David L Steward, James P Fidler, Thomas J Giordano, Paul W Biddinger, Yuri E Nikiforov. Am J Surg Pathol 2006
336
8


Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
267
8

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Marina N Nikiforova, Roy A Lynch, Paul W Biddinger, Erik K Alexander, Gerald W Dorn, Giovanni Tallini, Todd G Kroll, Yuri E Nikiforov. J Clin Endocrinol Metab 2003
472
8

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.
Yuri E Nikiforov, Raja R Seethala, Giovanni Tallini, Zubair W Baloch, Fulvio Basolo, Lester D R Thompson, Justine A Barletta, Bruce M Wenig, Abir Al Ghuzlan, Kennichi Kakudo,[...]. JAMA Oncol 2016
738
8

BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Carol Li, Kathleen C Lee, Eric B Schneider, Martha A Zeiger. J Clin Endocrinol Metab 2012
162
8

Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Dingxie Liu, Shuiying Hu, Peng Hou, David Jiang, Stephen Condouris, Mingzhao Xing. Clin Cancer Res 2007
130
7


Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
820
7

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
7

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
303
7

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xiulong Xu, Roderick M Quiros, Paolo Gattuso, Kenneth B Ain, Richard A Prinz. Cancer Res 2003
348
7

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
325
7

BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
Vítor Trovisco, Inês Vieira de Castro, Paula Soares, Valdemar Máximo, Paula Silva, João Magalhães, Alexander Abrosimov, Xavier Matias Guiu, Manuel Sobrinho-Simões. J Pathol 2004
283
7

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
7



Thyroid cancer mortality and incidence: a global overview.
Carlo La Vecchia, Matteo Malvezzi, Cristina Bosetti, Werner Garavello, Paola Bertuccio, Fabio Levi, Eva Negri. Int J Cancer 2015
495
7

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
981
7

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
M Grieco, M Santoro, M T Berlingieri, R M Melillo, R Donghi, I Bongarzone, M A Pierotti, G Della Porta, A Fusco, G Vecchio. Cell 1990
805
6

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
142
6

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A Knauf, Xiao-Hui Liao, Brian L West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen,[...]. J Clin Invest 2011
209
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.